Tirzepatide: A Research Overview

Tirzepatide has become a reference point in metabolic peptide research. It is a “dual agonist”, meaning it acts on two receptors at the same time — and that combination is exactly what has made it so widely studied.

GLP-1 and GIP — two pathways, one molecule

Tirzepatide engages both the GLP-1 receptor and the GIP receptor. Both are incretin receptors, part of the system the body uses to regulate glucose and energy balance. Studying them together, through a single molecule, lets researchers explore how the two pathways interact — something that is difficult to do with separate single-target compounds.

Why tirzepatide is a research benchmark

Because it was one of the first dual incretin agonists to be widely characterised, tirzepatide is often used as a comparison point in the literature. When newer peptides such as retatrutide are investigated, they are frequently measured against tirzepatide’s dual-receptor profile, making it a kind of baseline for multi-agonist research.

Formats available

Auriva supplies tirzepatide as lyophilised vials and as pre-filled pens, across multiple strengths. Vials give laboratories full control over reconstitution and measurement; pens offer a convenient, ready-to-handle alternative. The choice comes down to how a particular lab prefers to work.

Handling and storage

Lyophilised tirzepatide is stored cool and away from light, and handled per standard laboratory practice to preserve integrity. As with all Auriva vials, complimentary bacteriostatic water is included, with an optional pre-mix service.

Important

Tirzepatide is supplied strictly for laboratory, analytical and research purposes only. It is not for human consumption and is not a medicine. Customers are responsible for lawful purchase and use within their jurisdiction.

Browse Auriva’s research-grade tirzepatide — pens and vials — with free BAC water and next day UK delivery.